- Home
- LXEH vs GLMD Comparison
LXEH vs GLMD Comparison
Compare LXEH & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | GLMD |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.6M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LXEH | GLMD |
|---|---|---|
| Price | $0.27 | $1.06 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 221.4K | ★ 6.3M |
| Earning Date | 12-30-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,585,942.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $0.74 |
| 52 Week High | $50.08 | $3.61 |
Technical Indicators
Market Signals| Indicator | LXEH | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 27.92 | 47.38 |
| Support Level | $0.31 | $0.81 |
| Resistance Level | $0.33 | $0.99 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 12.92 | 68.82 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.